The European Society of Endocrinology (ESE) has published a Revised Clinical Practice Guideline for the Treatment of Chronic ...

The European Society of Endocrinology (ESE) has published an open access Revised Clinical Practice Guideline for the ...

Revised Guideline published 10 years after original Guideline, key differences include redefinition and practical treatment ...

The European Society of Endocrinology (ESE) has published an open access Revised Clinical Practice Guideline for the Treatment of Chronic ...

JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera” or the "Company”), a leader in the ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million ...

Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® – Q3 2025 operating profit of €11.0 million – TransCon® CNP (navepegritide) under FDA Priority Review for the treatment ...

Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross ...

AstraZeneca has added a late-stage rare disease therapy to its pipeline, buying France’s Amolyt Pharma and its hypoparathyroidism drug eneboparatide for $800 million upfront. The bolt-on deal, which ...

Ascendis Pharma A/S ( ($ASND) ) has released its Q3 earnings. Here is a breakdown of the information Ascendis Pharma A/S presented to its ...

MBX Biosciences, Inc. ( (MBX) ) has shared an announcement.